肿瘤蛋白 53 突变在具有不规则 CD19 标志物表达的弥漫性大 B 细胞淋巴瘤中更为丰富。
Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.
机构信息
Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.
出版信息
Sci Rep. 2017 May 8;7(1):1566. doi: 10.1038/s41598-017-01800-6.
Accumulating evidence suggests tumor protein 53 (p53) promotes correct cellular differentiation. Thus, mutant TP53 may be more frequent in tumors with irregular differentiation. This study investigated whether TP53 mutations were more frequent in diffuse large B cell lymphoma (DLBCL) that lacked the B cell lineage marker CD19. Sixteen CD19 negative and 78 CD19 positive DLBCL were sequenced for TP53 mutations. Twenty nine tumors had TP53 mutations and were associated with poorer survival. Mutant TP53 was more frequent in CD19 negative lymphomas (81% versus 21%, p < 0.0001). Analysis of other B cell markers revealed a lack of paired box 5 (PAX5) in CD19 positive lymphomas with mutant TP53 (50%), which was more frequent compared to tumors with wild-type TP53 (15%, p = 0.002). In summary, DLBCL lacking CD19 or PAX5 expression were more likely to have mutant TP53, suggesting irregular B cell marker phenotypes are associated with TP53 mutation.
越来越多的证据表明肿瘤蛋白 53（p53）促进细胞的正确分化。因此，在分化不规则的肿瘤中，突变型 TP53 可能更为常见。本研究调查了缺乏 B 细胞谱系标志物 CD19 的弥漫性大 B 细胞淋巴瘤（DLBCL）中是否存在更多的 TP53 突变。对 16 例 CD19 阴性和 78 例 CD19 阳性的 DLBCL 进行了 TP53 突变测序。有 29 例肿瘤存在 TP53 突变，与生存率降低相关。突变型 TP53 在 CD19 阴性淋巴瘤中更为常见（81%对 21%，p<0.0001）。对其他 B 细胞标志物的分析显示，在具有突变型 TP53 的 CD19 阳性淋巴瘤中缺乏配对盒 5（PAX5）（50%，与具有野生型 TP53 的肿瘤相比更为常见（15%，p=0.002）。总之，缺乏 CD19 或 PAX5 表达的 DLBCL 更有可能存在突变型 TP53，这表明不规则的 B 细胞标志物表型与 TP53 突变相关。
Zotero 插件